Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.39 |
| ▸ | HRH2 | P25021 | 4/20 | 0.39 |
| ▸ | HRH1 | P35367 | 4/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4502666 | 0.96 | KCNH2 (0.42) | KCNH2HRH3HRH2HRH1MAOA | |
| SCHEMBL4511527 | 0.95 | KCNH2 (0.42) | KCNH2HRH3HRH2HRH1MAOA | |
| SCHEMBL4512830 | 0.95 | KCNH2 (0.49) | KCNH2HRH3S1PR5 | |
| SCHEMBL4513527 | 0.95 | KCNH2 (0.43) | KCNH2HRH3HRH2HRH1MAOB | |
| SCHEMBL4521345 | 0.95 | KCNH2 (0.41) | KCNH2HRH3S1PR1S1PR5 | |
| SCHEMBL4517137 | 0.94 | KCNH2 (0.42) | KCNH2HRH3HRH2HRH1MAOA | |
| SCHEMBL4510305 | 0.94 | KCNH2 (0.42) | KCNH2HRH3HRH2HRH1MAOA | |
| SCHEMBL4508497 | 0.93 | KCNH2 (0.42) | KCNH2HRH3HRH2HRH1MAOA | |
| SCHEMBL4516241 | 0.93 | KCNH2 (0.42) | KCNH2HRH3HRH2HRH1S1PR1 | |
| SCHEMBL4515390 | 0.92 | KCNH2 (0.45) | KCNH2HRH3HRH2HRH1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099162-A2 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | claimed |
| US-20080249086-A1 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2008-10-09 | — | — | US | claimed |
| US-7354917-B2 | Oxabispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2008-04-08 | — | — | US | claimed |
| US-20070259864-A1 | Novel Oxabispidine Compounds and Their Use in the Treatment of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| EP-1765831-A1 | NOVEL OXABISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | claimed |
| WO-2005123747-A1 | NOVEL OXABISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | claimed |
| US-20090099162-A2 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20080319198-A2 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080249086-A1 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2008-10-09 | — | — | US | disclosed |
| US-20080207899-A1 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-20080146812-A1 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| US-7354917-B2 | Oxabispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2008-04-08 | — | — | US | disclosed |
| US-20070259864-A1 | Novel Oxabispidine Compounds and Their Use in the Treatment of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| EP-1765831-A1 | NOVEL OXABISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123747-A1 | NOVEL OXABISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099162-A2 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | RYR1, KCNH1, CACNA1E | KCNH2 14/4885HRH3 452/4885HRH2 583/4885 |
| US-20080207899-A1 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | RYR1, KCNH1, CACNA1E | KCNH2 14/4885HRH3 452/4885HRH2 583/4885 |
| US-20070259864-A1 | Novel Oxabispidine Compounds and Their Use in the Treatment of Cardiac Arrhythmias | RYR1, KCNH1, CACNA1E | KCNH2 14/4885HRH3 452/4885HRH2 583/4885 |
| US-20080146812-A1 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | RYR1, KCNH1, CACNA1E | KCNH2 14/4885HRH3 452/4885HRH2 583/4885 |
| US-20080319198-A2 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | RYR1, KCNH1, CACNA1E | KCNH2 14/4885HRH3 452/4885HRH2 583/4885 |
| US-20080249086-A1 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | RYR1, KCNH1, CACNA1E | KCNH2 14/4885HRH3 452/4885HRH2 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.